bioAffinity Technologies (BIAF) Fundamentals 2026 — Revenue Analysis | SniperIQ
bioAffinity Technologies (BIAF) is a US-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of
bioAffinity Technologies (BIAF) has a market capitalization of approximately
bioAffinity Technologies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
bioAffinity Technologies runs a net profit margin of -280.6%, a gross margin of 22.1%, and an operating margin of -204.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
bioAffinity Technologies reported revenue of $6M for fiscal year 2025, with net income of -
bioAffinity Technologies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
bioAffinity Technologies carries a debt-to-equity ratio of 0.38x and a current ratio of 1.36x, with a market beta of -1.11. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For bioAffinity Technologies (BIAF) the key facts are: market cap
Get bioAffinity Technologies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.